NCT00001103

Brief Summary

The purpose of this study is to see whether anti-HIV drugs that reduce HIV in the blood also reduce HIV in the cerebrospinal fluid (CSF). CSF is the fluid found around the brain and spinal cord. This study also looks at whether reducing HIV in the CSF can help protect brain function. HIV can be detected in the brain and CSF early in HIV disease. Anti-HIV drugs probably reduce HIV in the CSF. This may be important because other studies have suggested high CSF HIV levels may lead to some loss of brain function.

Trial Health

85
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
2 countries

26 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

July 29, 2008

Status Verified

May 1, 2006

First QC Date

November 2, 1999

Last Update Submit

July 28, 2008

Conditions

Keywords

Neuropsychological TestsHIV-1RNA, ViralAnti-HIV AgentsViral Load

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Are HIV-positive.
  • Have levels of CD4 cells (immune cells that fight infection) less than 200 cells/mm3 and viral loads (level of HIV in the blood) greater than 2,000 copies/ml or viral loads greater than 50,000 copies/ml and any CD4 cell levels.
  • Are either: 1) starting a new potent antiretroviral therapy for HIV; 2) enrolling in a potent antiretroviral trial; or 3) currently participating in an ongoing antiretroviral trial or in clinical care and will be changing treatment due to treatment failure. The entry visit for ACTG 736 must occur before starting the treatment or before changing to the new treatment. (This study has been changed to include patients who have changed treatment due to treatment failure and those who are starting a new anti-HIV regimen.)

You may not qualify if:

  • Have an infection or cancer in the brain or certain diseases of the brain or nervous system.
  • Have a serious psychiatric illness (such as schizophrenia or severe depression).
  • Have completed treatment for a significant infection within 4 weeks of beginning the study (but certain drugs that fight infection are allowed on this study).
  • Are taking drugs to prevent or dissolve blood clots.
  • Abuse drugs or alcohol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (26)

Willow Clinic

Menlo Park, California, 94025, United States

Location

Univ of California / San Diego Treatment Ctr

San Diego, California, 921036325, United States

Location

San Francisco Gen Hosp

San Francisco, California, 941102859, United States

Location

San Mateo AIDS Program / Stanford Univ

Stanford, California, 943055107, United States

Location

Stanford Univ Med Ctr

Stanford, California, 943055107, United States

Location

Univ of Colorado Health Sciences Ctr

Denver, Colorado, 80262, United States

Location

Univ of Hawaii

Honolulu, Hawaii, 96816-2396, United States

Location

Northwestern Univ Med School

Chicago, Illinois, 60611, United States

Location

Johns Hopkins Hosp

Baltimore, Maryland, 21287, United States

Location

Beth Israel Med Ctr

New York, New York, 10003, United States

Location

Bellevue Hosp / New York Univ Med Ctr

New York, New York, 10016, United States

Location

Mount Sinai Med Ctr

New York, New York, 10029, United States

Location

Columbia Presbyterian Med Ctr

New York, New York, 10032, United States

Location

Univ of Rochester Medical Center

Rochester, New York, 14642, United States

Location

Univ of Cincinnati

Cincinnati, Ohio, 452670405, United States

Location

Case Western Reserve Univ

Cleveland, Ohio, 44106, United States

Location

MetroHealth Med Ctr

Cleveland, Ohio, 441091998, United States

Location

Ohio State Univ Hosp Clinic

Columbus, Ohio, 432101228, United States

Location

Univ of Pennsylvania at Philadelphia

Philadelphia, Pennsylvania, 19104, United States

Location

Univ of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States

Location

Miriam Hosp / Brown Univ

Providence, Rhode Island, 02906, United States

Location

Julio Arroyo

West Columbia, South Carolina, 29169, United States

Location

Comprehensive Care Clinic

Nashville, Tennessee, 37203, United States

Location

Univ of Texas, Southwestern Med Ctr of Dallas

Dallas, Texas, 75390, United States

Location

Univ of Washington

Seattle, Washington, 98104, United States

Location

Univ of Puerto Rico

San Juan, 009365067, Puerto Rico

Location

MeSH Terms

Conditions

Cognitive DysfunctionHIV Infections

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Christina Marra, MD

    University of Washington

    STUDY CHAIR
  • Kevin Robertson, PhD

    University of North Carolina, Chapel Hill

    STUDY CHAIR

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

July 29, 2008

Record last verified: 2006-05

Locations